- Conditions
- Alcohol Use Disorder
- Interventions
- Brief Family-Involved Treatment (B-FIT), Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD)
- Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1177–1200
of 13,968
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD, aGVHD
- Interventions
- Itolizumab, EQ001 Placebo
- Biological · Drug
- Lead sponsor
- Equillium
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 31 more
- Conditions
- AML
- Interventions
- Sirolimus, Mitoxantrone, Etoposide, Cytarabine
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Alzheimer's Disease
- Interventions
- PF-04447943, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Glendale, California • Gainesville, Florida • Hallandale, Florida
- Conditions
- Liver Cirrhosis
- Interventions
- Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part B: placebo (matching zibotentan capsule) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin, Part B: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose C) + dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Pasadena, California • San Francisco, California + 8 more
- Conditions
- Relapsed and Refractory Multiple Myeloma
- Interventions
- Selinexor, Venetoclax, Dexamethasone
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 3
- States / cities
- Coral Gables, Florida • Deerfield Beach, Florida • Miami, Florida
- Conditions
- Pancreatic Cancer, Advanced Cancer
- Interventions
- Hydroxychloroquine Sulfate, LY3214996
- Drug
- Lead sponsor
- Kimberly Perez, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Chapel Hill, North Carolina
- Conditions
- Hypertension, High Blood Pressure, Ventricular Hypertrophy, Diastolic Dysfunction, Systolic Dysfunction
- Interventions
- Exercise, Weight Loss, Low Sodium Diet, Smoking Cessation, Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)
- Behavioral · Drug
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Prostate Cancer
- Interventions
- Tinengotinib, abiraterone acetate with prednisone, Enzalutamide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 12
- States / cities
- New Haven, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 8 more
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Dolutegravir
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Los Angeles, California • San Diego, California • Providence, Rhode Island
- Conditions
- NSCLC Stage IV, Metastatic Non-Small Cell Lung Cancer
- Interventions
- Pembrolizumab, PEMETREXED, CARBOPLATIN, PACLITAXEL, InVision
- Drug · Diagnostic Test
- Lead sponsor
- Julia K. Rotow, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Brighton, Massachusetts • South Weymouth, Massachusetts
- Conditions
- Anxiety
- Interventions
- Trauma-informed yoga video recording
- Behavioral
- Lead sponsor
- National University of Natural Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 212 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Mycobacterium Avium-Intracellulare Infection, HIV Infections
- Interventions
- Ethambutol hydrochloride, Clarithromycin, Rifabutin
- Drug
- Lead sponsor
- Pharmacia
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Harbor City, California • Irvine, California + 34 more
- Conditions
- Tumor, Solid
- Interventions
- BDB001 (EIK1001), Atezolizumab
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Sarasota, Florida • Nashville, Tennessee + 1 more
- Conditions
- HIV Infections
- Interventions
- Methadone hydrochloride, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Solid Tumors
- Interventions
- Atezolizumab, Selicrelumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Recurrent Prostate Carcinoma
- Interventions
- High-Dose Rate Brachytherapy, Hyperthermia Treatment, Laboratory Biomarker Analysis
- Radiation · Procedure · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- Sitravatinib, Nivolumab
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- filgrastim, carboplatin, carmustine, cisplatin, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2004
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Depression, Obesity
- Interventions
- Accept Yourself!, Weight Watchers
- Behavioral
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bevacizumab, erlotinib hydrochloride, everolimus
- Biological · Drug
- Lead sponsor
- Herbert Hurwitz, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Neoplasms, Breast
- Interventions
- pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, lapatinib (GW572016) 1000 mg, pazopanib (GW786034) 800 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 19
- States / cities
- Jonesboro, Arkansas • Alhambra, California • Bakersfield, California + 16 more
- Conditions
- Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
- Interventions
- Radiation Therapy, AZD1390
- Radiation · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel, AZD2287 (Imaging agent)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 12
- States / cities
- Duarte, California • Encino, California • South Pasadena, California + 9 more